Bio-Rad Q3 sales $680.8M (-8.9% YoY); non-GAAP EPS $2.60 vs $3.71; FY22 guidance reaffirmed

BIO-RAD LABORATORIES, INC.

2022-Q3 EPS reported -$149.60 revenue$2,071,961,000

Q3 net sales $680.8M, down 8.9% YoY; currency-neutral core sales (ex-COVID and legal settlements) grew 6.1%.
GAAP net loss $164.2M ($5.52 loss per diluted share) vs income $3,928M in Q3 2021, driven by Sartorius fair-value swings.
Non-GAAP net income $77.9M ($2.60 diluted EPS) vs $112.2M ($3.71) in Q3 2021.
Life Science segment sales $317.9M (-14.9% YoY); Clinical Diagnostics $361.9M (-2.8% YoY; +3.0% currency-neutral).
FY22 guidance: non-GAAP currency-neutral revenue growth at high end of prior 1.0-2.0%; COVID revenue now ~$105M; operating margin ~19.0%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2022 results: revenue $680.8 million, net income $164.2 million, or a loss of $5.52 per share, on a diluted basis.

Period: the third quarter ended September 30, 2022
Revenue: $680.8 million
Net income: $164.2 million, or a loss of $5.52 per share, on a diluted basis
Result: reported results

Exact text from the filing

in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent compared to $747.0 million reported for the third quarter of 2021. COVID-related revenue was approximately $17 million in the third quarter of 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-RAD LABORATORIES, INC. filing history →

Source: SEC EDGAR

accession 0000012208-22-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.